Abrocitinib: A comprehensive review of its use in dermatology beyond atopic dermatitis.
Janus kinase (JAK) inhibitors are small molecule inhibitors that restrict proinflammatory pathways and are used in various autoimmune and inflammatory conditions, thus gaining significant threshold in dermatology. Abrocitinib, a JAK 1 inhibitor, was first approved in 2021 for use in atopic dermatiti...
| Published in: | Indian Journal of Skin Allergy Vol. 4; no. 1; pp. 1 - 19 |
|---|---|
| Main Authors: | , |
| Format: | review tables/charts Journal Article |
| Published: |
Scientific Scholar LLC
Jan-Jun2025
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=186922960&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 186922960 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 28340671 MY6M jtl: Indian Journal of Skin Allergy issn: 28340671 maglogo: N pubinfo: dt: Jan-Jun2025 vid: 4 iid: 1 pid: 56013 pub: Scientific Scholar LLC place: Pittsford, New York artinfo: ui: 186922960 186922960 186922960 10.25259/IJSA_54_2024 186922960 ppf: 1 ppct: 18 formats: tig: atl: Abrocitinib: A comprehensive review of its use in dermatology beyond atopic dermatitis. aug: au: Ray, Arunima Pandhi, Deepika affil: Department of Dermatology, Narayana Health - Rabindranath Tagore Institute of Cardiac Sciences, Kolkata, West Bengal, India. sug: subj: Dermatitis, Atopic Drug Therapy Janus Kinase Inhibitors Therapeutic Use Drug Efficacy Evaluation Janus Kinase Inhibitors Pharmacokinetics Janus Kinase Inhibitors Pharmacodynamics Janus Kinase Inhibitors Administration and Dosage Janus Kinase Inhibitors Metabolism Alopecia Areata Drug Therapy Lichen Sclerosus et Atrophicus Drug Therapy Livedoid Vasculopathy Drug Therapy Pyoderma Gangrenosum Drug Therapy Necrobiotic Disorders Drug Therapy Hidradenitis Suppurativa Drug Therapy Vitiligo Drug Therapy Lichen Planus, Oral Drug Therapy Dermatitis, Contact Drug Therapy Prurigo Drug Therapy Eczema Drug Therapy Pruritus Drug Therapy Janus Kinase Inhibitors Contraindications Janus Kinase Inhibitors Immunology Janus Kinase Inhibitors Adverse Effects Drug Interactions Janus Kinase Inhibitors Economics ab: Janus kinase (JAK) inhibitors are small molecule inhibitors that restrict proinflammatory pathways and are used in various autoimmune and inflammatory conditions, thus gaining significant threshold in dermatology. Abrocitinib, a JAK 1 inhibitor, was first approved in 2021 for use in atopic dermatitis (AD) and has been shown to be effective and safe in most cases. Since its approval, abrocitinib has also been reported to be varyingly successful in a group of other dermatological conditions and is a relatively safe drug. Our comprehensive review is based on an extensive PubMed search of all published literature on the use of abrocitinib in dermatological disorders with the exclusion of AD whereby we identified and included 37 papers. These include diverse eczematous, autoimmune, inflammatory, and keratinization disorders. Beyond AD, the largest number of patients were reported for vitiligo, hand eczema, chronic pruritus, and prurigo nodularis, all of which reported favorable outcomes. Pharmacodynamic studies have shown a dose-dependent decrease in platelet counts and disruption in lipid levels. Other mild adverse effects include nausea and dizziness which do not merit drug discontinuation. Our review highlights the broad usefulness that abrocitinib has as a therapeutic agent in inflammatory and autoimmune dermatoses, often when used as a single therapeutic agent, and has predictable safety and tolerability profiles. A larger number of randomized controlled trials are required to validate the off-label uses of abrocitinib and to optimize dosing strategies. This review also includes information about dosing recommendations, drug monitoring, and the use of oral abrocitinib in special patient groups. pubtype: Academic Journal doctype: review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|